Primary versus castration-resistant prostate cancer: modeling through novel murine prostate cancer cell lines

被引:13
作者
Daoud, Georges [1 ]
Monzer, Alissar [1 ]
Bahmad, Hisham [1 ]
Chamaa, Farah [1 ]
Hamdar, Layal [1 ]
Mouhieddine, Tarek H. [1 ]
Shayya, Sami [1 ]
Eid, Assaad [1 ]
Kobeissy, Firas [2 ]
Liu, Yen-Nien [3 ]
Abou-Kheir, Wassim [1 ]
机构
[1] Amer Univ Beirut, Dept Anat Cell Biol & Physiol Sci, Fac Med, Beirut, Lebanon
[2] Amer Univ Beirut, Dept Biochem & Mol Genet, Fac Med, Beirut, Lebanon
[3] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei, Taiwan
关键词
prostate cancer; castration-resistant prostate cancer; cancer stem cells; Pten; TP53; OXIDATIVE STRESS; EXPRESSION; TRANSITION; MECHANISMS; DOCETAXEL; GROWTH; BETA;
D O I
10.18632/oncotarget.8436
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cell lines representing the progression of prostate cancer (PC) from an androgen-dependent to an androgen-independent state are scarce. In this study, we used previously characterized prostate luminal epithelial cell line (Plum), under androgen influence, to establish cellular models of PC progression. Cells derived from orthotopic tumors have been isolated to develop an androgen-dependent (PLum-AD) versus an androgen-independent (PLum-AI) model. Upon immunofluorescent, qRT-PCR and Western blot analyses, PLum-AD cells mostly expressed prostate epithelial markers while PLum-AI cells expressed mesenchymal cell markers. Interestingly, both cell lines maintained a population of stem/progenitor cells. Furthermore, our data suggest that both cell lines are tumorigenic; PLum-AD resulted in an adenocarcinoma whereas PLum-AI resulted in a sarcomatoid carcinoma when transplanted subcutaneously in NOD-SCID mice. Finally, gene expression profiles showed enrichment in functions involved in cell migration, apoptosis, as well as neoplasm invasiveness and metastasis in PLum-AI cells. In conclusion, these data suggest that the newly isolated cell lines represent a new in vitro model of androgen-dependent and -independent PC.
引用
收藏
页码:28961 / 28975
页数:15
相关论文
共 50 条
  • [21] Novel agents for the management of castration-resistant prostate cancer
    Haddad, Housam
    Garcia, Jorge A.
    CURRENT OPINION IN UROLOGY, 2012, 22 (03) : 175 - 182
  • [22] Novel Strategies for Treating Castration-Resistant Prostate Cancer
    Leung, David Ka-Wai
    Chiu, Peter Ka-Fung
    Ng, Chi-Fai
    Teoh, Jeremy Yuen-Chun
    BIOMEDICINES, 2021, 9 (04)
  • [23] Novel options for the treatment of castration-resistant prostate cancer
    Carsten-H. Ohlmann
    Axel S. Merseburger
    Henrik Suttmann
    David Schilling
    Lutz Trojan
    Carsten Kempkensteffen
    Stefan Corvin
    Michael J. Mathers
    Patrick J. Bastian
    World Journal of Urology, 2012, 30 : 495 - 503
  • [24] Effect of simvastatin on castration-resistant prostate cancer cells
    Kim, Jenny Hanbi
    Cox, Michael E.
    Wasan, Kishor M.
    LIPIDS IN HEALTH AND DISEASE, 2014, 13
  • [25] Satraplatin for the therapy of castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    FUTURE ONCOLOGY, 2009, 5 (07) : 931 - 940
  • [26] Effect of dutasteride on castration-resistant prostate cancer
    Azuma, Takeshi
    Matayoshi, Yukihide
    Sato, Yujiro
    Nagase, Yasuhi
    MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (01) : 133 - 136
  • [27] Cabazitaxel for the treatment of castration-resistant prostate cancer
    Agarwal, Neeraj
    Sonpavde, Guru
    Sartor, Oliver
    FUTURE ONCOLOGY, 2011, 7 (01) : 15 - 24
  • [28] Sequencing Treatment for Castration-Resistant Prostate Cancer
    Handy, Catherine E.
    Antonarakis, Emmanuel S.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)
  • [29] The Molecular Evolution of Castration-resistant Prostate Cancer
    Ceder, Yvonne
    Bjartell, Anders
    Culig, Zoran
    Rubin, Mark A.
    Tomlins, Scott
    Visakorpi, Tapio
    EUROPEAN UROLOGY FOCUS, 2016, 2 (05): : 506 - 513
  • [30] The role of microRNA in castration-resistant prostate cancer
    Thieu, William
    Tilki, Derya
    White, Ralph W. deVere
    Evans, Christopher P.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (05) : 517 - 523